Voyager Therapeutics (VYGR) Accumulated Expenses: 2015-2025
Historic Accumulated Expenses for Voyager Therapeutics (VYGR) over the last 10 years, with Sep 2025 value amounting to $15.0 million.
- Voyager Therapeutics' Accumulated Expenses rose 30.69% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 30.69%. This contributed to the annual value of $14.2 million for FY2024, which is 15.76% down from last year.
- According to the latest figures from Q3 2025, Voyager Therapeutics' Accumulated Expenses is $15.0 million, which was up 24.35% from $12.0 million recorded in Q2 2025.
- Voyager Therapeutics' 5-year Accumulated Expenses high stood at $16.8 million for Q4 2023, and its period low was $7.2 million during Q2 2022.
- Moreover, its 3-year median value for Accumulated Expenses was $11.1 million (2023), whereas its average is $11.3 million.
- As far as peak fluctuations go, Voyager Therapeutics' Accumulated Expenses tumbled by 47.73% in 2021, and later surged by 115.24% in 2023.
- Quarterly analysis of 5 years shows Voyager Therapeutics' Accumulated Expenses stood at $10.9 million in 2021, then declined by 28.62% to $7.8 million in 2022, then spiked by 115.24% to $16.8 million in 2023, then declined by 15.76% to $14.2 million in 2024, then spiked by 30.69% to $15.0 million in 2025.
- Its Accumulated Expenses stands at $15.0 million for Q3 2025, versus $12.0 million for Q2 2025 and $9.1 million for Q1 2025.